Almirall builds on biologics as first-half earnings climb

Spanish medical dermatology company Almirall (BME: ALM) has reported first-half 2026 net sales of 602.7 million euros ($687.1 million), up 7.5% year on year, with profits rising far faster than the top line. Net income jumped 49.4% to 39.6 million euros, while core earnings, or EBITDA, climbed 23.7% to 150.7 million euros.

Growth was led by the European dermatology business, where sales rose 18.1% to 341.9 million euros. The biologics portfolio did much of the heavy lifting. Atopic dermatitis treatment Ebglyss (lebrikizumab) nearly doubled to 84.5 million euros, up 88.2%, and plaque psoriasis drug Ilumetri (tildrakizumab) grew 10.5% to 125.2 million euros.